ACTINIUM PHARMACEUTICALS INC (ATNM) Fundamental Analysis & Valuation

NYSEARCA:ATNM • US00507W2061

1.13 USD
-0.05 (-4.24%)
Last: Mar 12, 2026, 08:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ATNM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

ATNM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. ATNM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. ATNM Profitability Analysis

1.1 Basic Checks

  • In the past year ATNM has reported negative net income.
  • In the past year ATNM has reported a negative cash flow from operations.
  • ATNM had negative earnings in each of the past 5 years.
  • In the past 5 years ATNM reported 4 times negative operating cash flow.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • ATNM has a Return On Assets of -65.12%. This is in the lower half of the industry: ATNM underperforms 60.69% of its industry peers.
  • The Return On Equity of ATNM (-215.83%) is worse than 69.17% of its industry peers.
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • ATNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ATNM Health Analysis

2.1 Basic Checks

  • ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ATNM has more shares outstanding than it did 1 year ago.
  • ATNM has more shares outstanding than it did 5 years ago.
  • ATNM has a better debt/assets ratio than last year.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • ATNM has an Altman-Z score of -9.67. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
  • ATNM has a worse Altman-Z score (-9.67) than 72.06% of its industry peers.
  • ATNM has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • ATNM has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.67
ROIC/WACCN/A
WACC8.85%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • ATNM has a Current Ratio of 7.34. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.34, ATNM is in the better half of the industry, outperforming 70.13% of the companies in the same industry.
  • A Quick Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
  • ATNM's Quick ratio of 7.34 is fine compared to the rest of the industry. ATNM outperforms 70.13% of its industry peers.
Industry RankSector Rank
Current Ratio 7.34
Quick Ratio 7.34
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ATNM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.43% over the past year.
  • ATNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ATNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.16% yearly.
  • The Revenue is expected to grow by 265.08% on average over the next years. This is a very strong growth
EPS Next Y13.26%
EPS Next 2Y18.45%
EPS Next 3Y13.56%
EPS Next 5Y13.16%
Revenue Next Year-52.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y508.68%
Revenue Next 5Y265.08%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATNM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATNM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ATNM's earnings are expected to grow with 13.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.45%
EPS Next 3Y13.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATNM Dividend Analysis

5.1 Amount

  • No dividends for ATNM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATNM Fundamentals: All Metrics, Ratios and Statistics

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (3/12/2026, 8:23:54 PM)

1.13

-0.05 (-4.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners20.62%
Inst Owner Change2.79%
Ins Owners2.36%
Ins Owner Change0%
Market Cap35.26M
Revenue(TTM)N/A
Net Income(TTM)-41.04M
Analysts81.82
Price Target5.1 (351.33%)
Short Float %3.48%
Short Ratio8.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.9%
Min EPS beat(2)-80.18%
Max EPS beat(2)38.38%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-80.18%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)2.81%
EPS beat(16)8
Avg EPS beat(16)-7.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)100%
Revenue NY rev (3m)100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.34
Quick Ratio 7.34
Altman-Z -9.67
F-Score2
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)25.77%
Cap/Depr(5y)31.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
EPS Next Y13.26%
EPS Next 2Y18.45%
EPS Next 3Y13.56%
EPS Next 5Y13.16%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-52.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y508.68%
Revenue Next 5Y265.08%
EBIT growth 1Y5.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.87%
EBIT Next 3Y1.85%
EBIT Next 5Y-1.39%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.29%
OCF growth 3YN/A
OCF growth 5YN/A

ACTINIUM PHARMACEUTICALS INC / ATNM FAQ

What is the fundamental rating for ATNM stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATNM.


Can you provide the valuation status for ACTINIUM PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ACTINIUM PHARMACEUTICALS INC (ATNM). This can be considered as Overvalued.


Can you provide the profitability details for ACTINIUM PHARMACEUTICALS INC?

ACTINIUM PHARMACEUTICALS INC (ATNM) has a profitability rating of 0 / 10.


Can you provide the financial health for ATNM stock?

The financial health rating of ACTINIUM PHARMACEUTICALS INC (ATNM) is 4 / 10.


What is the expected EPS growth for ACTINIUM PHARMACEUTICALS INC (ATNM) stock?

The Earnings per Share (EPS) of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to grow by 13.26% in the next year.